NO325630B1 - Dofetilidpolymorf, fremgangsmate for fremstilling derav samt anvendelse derav for fremstilling av medikamenter og medisinske preparater. - Google Patents

Dofetilidpolymorf, fremgangsmate for fremstilling derav samt anvendelse derav for fremstilling av medikamenter og medisinske preparater. Download PDF

Info

Publication number
NO325630B1
NO325630B1 NO20002191A NO20002191A NO325630B1 NO 325630 B1 NO325630 B1 NO 325630B1 NO 20002191 A NO20002191 A NO 20002191A NO 20002191 A NO20002191 A NO 20002191A NO 325630 B1 NO325630 B1 NO 325630B1
Authority
NO
Norway
Prior art keywords
dofetilide
polymorph
dofetilide polymorph
pure
pharmaceutically acceptable
Prior art date
Application number
NO20002191A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002191L (no
NO20002191D0 (no
Inventor
Ian Colin Appleby
Trevor Jack Newbury
Gary Nichols
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10821150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325630(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of NO20002191L publication Critical patent/NO20002191L/no
Publication of NO20002191D0 publication Critical patent/NO20002191D0/no
Publication of NO325630B1 publication Critical patent/NO325630B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20002191A 1997-10-27 2000-04-27 Dofetilidpolymorf, fremgangsmate for fremstilling derav samt anvendelse derav for fremstilling av medikamenter og medisinske preparater. NO325630B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9722662.5A GB9722662D0 (en) 1997-10-27 1997-10-27 Polymorphs
PCT/EP1998/006641 WO1999021829A1 (fr) 1997-10-27 1998-10-09 Polymorphes de dofetilide

Publications (3)

Publication Number Publication Date
NO20002191L NO20002191L (no) 2000-04-27
NO20002191D0 NO20002191D0 (no) 2000-04-27
NO325630B1 true NO325630B1 (no) 2008-06-30

Family

ID=10821150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002191A NO325630B1 (no) 1997-10-27 2000-04-27 Dofetilidpolymorf, fremgangsmate for fremstilling derav samt anvendelse derav for fremstilling av medikamenter og medisinske preparater.

Country Status (46)

Country Link
US (1) US6124363A (fr)
EP (1) EP1027329B1 (fr)
JP (1) JP3569495B2 (fr)
KR (1) KR100366167B1 (fr)
CN (1) CN1146537C (fr)
AP (1) AP906A (fr)
AR (1) AR015193A1 (fr)
AT (1) ATE232199T1 (fr)
AU (1) AU737668B2 (fr)
BG (1) BG64125B1 (fr)
BR (1) BR9813308A (fr)
CA (1) CA2307121C (fr)
CO (1) CO4970768A1 (fr)
DE (1) DE69811256T2 (fr)
DK (1) DK1027329T3 (fr)
DZ (1) DZ2632A1 (fr)
EA (1) EA002656B1 (fr)
ES (1) ES2190620T3 (fr)
GB (1) GB9722662D0 (fr)
GT (1) GT199800165A (fr)
HN (1) HN1998000165A (fr)
HR (1) HRP20000247B1 (fr)
HU (1) HUP0004735A3 (fr)
ID (1) ID24658A (fr)
IL (1) IL135435A0 (fr)
IS (1) IS2179B (fr)
MA (1) MA24683A1 (fr)
MY (1) MY123352A (fr)
NO (1) NO325630B1 (fr)
NZ (1) NZ503785A (fr)
OA (1) OA11350A (fr)
PA (1) PA8462001A1 (fr)
PE (1) PE122199A1 (fr)
PL (1) PL197379B1 (fr)
PT (1) PT1027329E (fr)
SA (1) SA98190834B1 (fr)
SI (1) SI1027329T1 (fr)
SK (1) SK5862000A3 (fr)
TN (1) TNSN98193A1 (fr)
TR (1) TR200001135T2 (fr)
TW (1) TW449589B (fr)
UA (1) UA67755C2 (fr)
UY (2) UY25222A1 (fr)
WO (1) WO1999021829A1 (fr)
YU (1) YU24000A (fr)
ZA (1) ZA989719B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (de) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermales Therapeutisches System zur Abgabe von Dofetilid und seine Verwendung
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
CZ307826B6 (cs) 2017-12-01 2019-05-29 Farmak, A.S. Způsob přípravy N-[4-(2-{[2-(4-methansulfonamidofenoxy)ethyl](methyl)amino}ethyl)fenyl]methansulfonamidu (Dofetilidu)
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
WO2026082696A1 (fr) 2024-10-14 2026-04-23 Hyloris Developments Sa Formulations de dofétilide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
EP0898964A1 (fr) * 1997-08-19 1999-03-03 Pfizer Inc. Traitement de la défaillance cardiaque

Also Published As

Publication number Publication date
KR100366167B1 (ko) 2003-01-09
DK1027329T3 (da) 2003-02-24
CN1146537C (zh) 2004-04-21
AU737668B2 (en) 2001-08-30
AU2151299A (en) 1999-05-17
ES2190620T3 (es) 2003-08-01
HRP20000247B1 (en) 2002-08-31
HN1998000165A (es) 1999-02-09
IS2179B (is) 2006-12-15
HK1033933A1 (en) 2001-10-05
UA67755C2 (uk) 2004-07-15
YU24000A (sh) 2003-02-28
PE122199A1 (es) 1999-12-02
ID24658A (id) 2000-07-27
SA98190834B1 (ar) 2006-08-21
AP9801371A0 (en) 1998-12-31
NO20002191L (no) 2000-04-27
HUP0004735A2 (hu) 2001-10-28
EP1027329A1 (fr) 2000-08-16
KR20010031439A (ko) 2001-04-16
BG104373A (en) 2000-12-29
HUP0004735A3 (en) 2001-12-28
IL135435A0 (en) 2001-05-20
EA200000365A1 (ru) 2000-12-25
IS5426A (is) 2000-03-31
CO4970768A1 (es) 2000-11-07
EP1027329B1 (fr) 2003-02-05
NZ503785A (en) 2004-11-26
PL197379B1 (pl) 2008-03-31
AP906A (en) 2000-11-30
TNSN98193A1 (fr) 2005-03-15
SK5862000A3 (en) 2001-10-08
TR200001135T2 (tr) 2000-09-21
PL340805A1 (en) 2001-02-26
DE69811256D1 (de) 2003-03-13
TW449589B (en) 2001-08-11
WO1999021829A1 (fr) 1999-05-06
CA2307121A1 (fr) 1999-05-06
PA8462001A1 (es) 2000-05-24
PT1027329E (pt) 2003-04-30
NO20002191D0 (no) 2000-04-27
UY25341A1 (es) 1999-09-27
GB9722662D0 (en) 1997-12-24
JP3569495B2 (ja) 2004-09-22
DZ2632A1 (fr) 2003-03-08
BG64125B1 (bg) 2004-01-30
BR9813308A (pt) 2000-08-22
MY123352A (en) 2006-05-31
ATE232199T1 (de) 2003-02-15
SI1027329T1 (en) 2003-04-30
UY25222A1 (es) 2000-12-29
ZA989719B (en) 2000-04-26
MA24683A1 (fr) 1999-07-01
CA2307121C (fr) 2006-12-05
AR015193A1 (es) 2001-04-18
HRP20000247A2 (en) 2000-10-31
EA002656B1 (ru) 2002-08-29
JP2001521023A (ja) 2001-11-06
GT199800165A (es) 2000-04-19
DE69811256T2 (de) 2003-09-18
CN1278246A (zh) 2000-12-27
OA11350A (en) 2003-12-17
US6124363A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
RU2467012C2 (ru) Способ очистки стауроспорина и способ получения n-бензоилстауроспорина
CN113784966A (zh) Glyt1抑制剂的固体形式
EA014164B1 (ru) Новая кристаллическая форма производного пиридазино[4,5-в]индола
EP1027329B1 (fr) Polymorphes de dofetilide
EP0161599A2 (fr) Dérivés de benzazépine, médicaments contenant les composés et procédé pour leur préparation
US6482939B1 (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)-1h-bezimimidazole
DE602004010837T2 (de) Pharmazeutische zusammensetzung auf basis eines idazoxan-salzes oder eines seiner polymorphen
KR100540021B1 (ko) 신규한 결정 구조를 갖는 에리트로마이신 유도체 및 그의제조 방법
US20030105360A1 (en) Form a of fluoxetine hydrochloride
MXPA00004059A (en) Dofetilide polymorphs
MXPA04005505A (es) Forma de farmaco cristalina.
EP1318150A1 (fr) Nouveaux cristaux de derive 1,3,4-oxadiazole, procede de production de ces cristaux, et medicament base de tels principes actifs
CZ20001516A3 (cs) Polymorfy dofetilidu
SE502323C2 (sv) Användning av N-(2-hydroxietyl)nikotinamidnitrat eller ett farmaceutiskt godtagbart salt därav för framställning av ett läkemedel aktivt för behandling av sjukdomar förbundna med cerebral ischemi
EP3356333A1 (fr) Formes cristallines d'un modulateur allostérique positif du récepteur m1
NO970183L (no) (1H-Indol-4-yl)-piperidin- eller tetrahydropyridin-etylaminer og -etylkarboksamider
EP0864572B1 (fr) Cristal d'hydrate et son procede de preparation
US6310251B1 (en) Form a of fluoxetine hydrochloride
CN118440065A (zh) 一种钠通道调节剂及其应用
EP4653441A1 (fr) Sel de composé antidépresseur, son procédé de préparation, composition pharmaceutique le contenant et son utilisation
EP1392696A1 (fr) Formes polymorphes de n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro 2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide
CN121591706A (zh) 一种4-硫代酰胺类取代的吡啶衍生物及其应用

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees